Moderna has scrapped plans to enroll a new cohort in a phase 3 trial of its norovirus vaccine and instead will meet with regulators to decide on next steps. | Moderna has scrapped plans to enroll a ...

Generate Biomedicines' CEO has hailed the “huge opportunity” offered by AI tools after the Flagship-founded company used ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Fernandes, Executive Vice President, Chief Business Officer at Ipsen | Science rarely moves in a straight line. Philippe Lopes-Fernandes explores how an unexpected turn can reveal a credible path to ...

Merck & Co. has called time on a Sutro Biopharma-partnered IL-2 agonist that was being tested for solid tumors, Fierce has ...

Evommune has agreed to pay $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular ...

The aim is to reduce the biopharma’s R&D workforce by more than 35% compared with 2025 levels, with the associated cost ...

Siemens Healthineers will carve out its in vitro diagnostics business as a standalone company operating under the name ...

Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves ...

MetaVia has linked its GLP-1/glucagon receptor agonist to reductions in liver fat and body weight in a phase 1 trial.

AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase ...

Ultragenyx is laying off 20% of its workforce and axing drug development programs to cut its annual R&D budget to half of the ...